TY - JOUR
T1 - Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
AU - Verbeek, Martijn W.C.
AU - Buracchi, Chiara
AU - Laqua, Anna
AU - Nierkens, Stefan
AU - Sedek, Lukasz
AU - Flores-Montero, Juan
AU - Hofmans, Mattias
AU - Sobral de Costa, Elaine
AU - Nováková, Michaela
AU - Mejstrikova, Ester
AU - Barrena, Susana
AU - Kohlscheen, Saskia
AU - Szczepanowski, Monika
AU - Kulis, Jan
AU - Oliveira, Elen
AU - Jugooa, Romana
AU - de Jong, Anja X.
AU - Szczepanski, Tomasz
AU - Philippé, Jan
AU - van Dongen, Jacques J.M.
AU - Orfao, Alberto
AU - Brüggemann, Monika
AU - Gaipa, Giuseppe
AU - van der Velden, Vincent H.J.
N1 - © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
PY - 2022/4
Y1 - 2022/4
N2 - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
AB - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
KW - acute leukaemia
KW - diagnostic haematology
KW - flow cytometry
KW - minimal residual disease
KW - Neoplasm, Residual
KW - Adaptor Proteins, Signal Transducing
KW - Antigens, CD19/therapeutic use
KW - Humans
KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
KW - Flow Cytometry/methods
KW - Burkitt Lymphoma
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma
UR - https://www.scopus.com/pages/publications/85120974952
U2 - 10.1111/bjh.17992
DO - 10.1111/bjh.17992
M3 - Article
C2 - 34881427
AN - SCOPUS:85120974952
SN - 0007-1048
VL - 197
SP - 76
EP - 81
JO - British journal of haematology
JF - British journal of haematology
IS - 1
ER -